We recently published a list of 10 Firms Crushing the Market. In this article, we are going to take a look at where Tempus AI ...

Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Tempus enters earnings with strong tailwinds but ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...